Validation of the GALAD model and establishment of a new model for HCC detection in Chinese patients
暂无分享,去创建一个
Hainv Gao | Zixuan Feng | Ping Chen | Haolin Song | Lanjuan Li | Chao-Ying Jin | Juhong Zhou | Yubo Cai | F. Lu | Wei Xu | Jianfei Wang | Jin Guo | Xi Kang
[1] J. Marrero,et al. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis , 2021, Hepatology.
[2] N. Chalasani,et al. Validation of a novel multi-target blood test shows high sensitivity to detect early-stage hepatocellular carcinoma. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[3] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[4] Xinyuan Zhang,et al. Prediction of late recurrence after radiofrequency ablation of HBV-related hepatocellular carcinoma with the age-male-albumin-bilirubin-platelets (aMAP) risk score: a multicenter study. , 2021, Journal of gastrointestinal oncology.
[5] J. Niu,et al. Validation of the GALAD Model and Establishment of GAAP Model for Diagnosis of Hepatocellular Carcinoma in Chinese Patients , 2020, Journal of hepatocellular carcinoma.
[6] N. Chalasani,et al. A Novel Blood-based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[7] R. Salgia,et al. The Changing Global Epidemiology of Hepatocellular Carcinoma. , 2020, Clinics in liver disease.
[8] M. Buti,et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. , 2020, Journal of hepatology.
[9] Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.
[10] T. Berg,et al. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[11] T. Murakami,et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update , 2019, Hepatology research : the official journal of the Japan Society of Hepatology.
[12] A. Villanueva. Hepatocellular Carcinoma. , 2019, The New England journal of medicine.
[13] G. Gores,et al. GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score , 2018, Cancer Epidemiology, Biomarkers & Prevention.
[14] Jinzhou Zhu,et al. Epidemiological Trends in Gastrointestinal Cancers in China: An Ecological Study , 2018, Digestive Diseases and Sciences.
[15] J. Marrero,et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. , 2018, Gastroenterology.
[16] J. Bruix,et al. Hepatocellular carcinoma , 2018, The Lancet.
[17] T. Therneau,et al. Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models , 2018, World journal of gastroenterology.
[18] M. Manns,et al. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[19] Ziding,et al. The Doylestown algorithm – a test to improve the performance of AFP in the detection of hepatocellular carcinoma , 2015 .
[20] K. McGlynn,et al. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. , 2015, Clinics in liver disease.
[21] S. Berhane,et al. Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model , 2014, British Journal of Cancer.
[22] P. Johnson,et al. P554 ASSESSMENT OF PROGNOSIS IN HEPATOCELLULAR CARCINOMA USING A BIOMARKER BASED APPROACH: VALIDATION AND EXTENSION OF THE BALAD MODEL , 2014 .
[23] H. Reeves,et al. The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[24] F. Schmidt. Meta-Analysis , 2008 .
[25] M. Kudo,et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[26] L. Webb,et al. An ecological study. , 1979, Science.